Concepedia

Elizabeth Alli

EA

Statistics

Publications

12

Citations

1K

H-Index

12

Active since

2002

Affiliations

Stanford University(Current)

Johnson University

Rutgers, The State University of New Jersey

Rutgers Cancer Institute

Stanford Medicine

Elizabeth Alli is an author at Stanford University specializing in oncology, medicine, and molecular oncology.

Publications per year

2002–2019

12

Publications

12

Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.

Elizabeth Alli, Judy Bash-Babula, Jin Yang et al. · PubMed · 2002 · 184 citations

, , +14

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin

Kedar Hastak, Elizabeth Alli, James M. Ford · Cancer Research · 2010 · 177 citations · Full text

, , +13

Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase

Elizabeth Alli, Vandana Sharma, Preethi Sunderesakumar et al. · Cancer Research · 2009 · 154 citations · Full text

, , +17

Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo

Jessica Swanner, Cale D. Fahrenholtz, Iliana Tenvooren et al. · FASEB BioAdvances · 2019 · 104 citations · Full text

, , +17

Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53

Elizabeth Alli, W N Hait · Oncogene · 2006 · 97 citations

, , +16

1–5 of 12